We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+8.13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.72B
AUM Growth
–
Cap. Flow
+$4.69B
Cap. Flow %
99.51%
Top 10 Hldgs %
37.69%
Holding
127
New
123
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$272M
2
GILD icon
Gilead Sciences
GILD
+$251M
3
BIIB icon
Biogen
BIIB
+$219M
4
MRK icon
Merck
MRK
+$193M
5
VTRS icon
Viatris
VTRS
+$149M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 80.02%
2 Financials 2.05%
3 Technology 0.14%
4 Utilities 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSUR icon
51
OraSure Technologies
OSUR
$276M
$18.5M 0.39%
+4,760,300
New +$21.2M
VRTX icon
52
Vertex Pharmaceuticals
VRTX
$124B
$17.9M 0.38%
+223,000
New +$16.4M
ALXN
53
DELISTED
Alexion Pharmaceuticals
ALXN
$17.8M 0.38%
+192,900
New +$18.6M
AGN
54
CALL
DELISTED
Allergan plc
AGN
$17.8M 0.38%
+140,700
New +$15.9M
JNJ icon
55
Johnson & Johnson
JNJ
$644B
$17.3M 0.37%
+201,000
New +$17.1M
DNDN
56
DELISTED
DENDREON CORPORATION
DNDN
$16.9M 0.36%
+4,102,300
New +$17.5M
ABT icon
57
Abbott
ABT
$190B
$16.7M 0.35%
+480,000
New +$17.6M
SUPN icon
58
Supernus Pharmaceuticals
SUPN
$2.77B
$16.1M 0.34%
+2,496,200
New +$14.7M
SQNM
59
DELISTED
SEQUENOM INC NEW
SQNM
$15.2M 0.32%
+3,603,000
New +$14.4M
PCRX icon
60
Pacira BioSciences
PCRX
$1.05B
$14.4M 0.31%
+498,000
New +$14.4M
BMY icon
61
CALL
Bristol-Myers Squibb
BMY
$130B
$13.4M 0.28%
+300,000
New +$13M
ASTX
62
DELISTED
ASTEX PHARMACEUTICALS, INC COM
ASTX
$13.4M 0.28%
+3,256,100
New +$17.5M
PBYI icon
63
Puma Biotechnology
PBYI
$404M
$13.1M 0.28%
+295,000
New +$10.4M
WCG
64
DELISTED
Wellcare Health Plans, Inc.
WCG
$12.9M 0.27%
+233,000
New +$13M
DRTX
65
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$12.9M 0.27%
+1,785,714
New +$13.1M
RCPT
66
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$12.8M 0.27%
+644,450
New +$10.9M
HITK
67
DELISTED
HI-TECH PHARMACAL INC
HITK
$12.3M 0.26%
+371,200
New +$12.4M
A icon
68
CALL
Agilent Technologies
A
$39.9B
$12M 0.25%
+393,257
New +$12.2M
BHC icon
69
Bausch Health
BHC
$1.68B
$11.9M 0.25%
+138,000
New +$10.9M
PTLA
70
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$11.8M 0.25%
+480,319
New +$9.55M
CYH icon
71
Community Health Systems
CYH
$392M
$11.3M 0.24%
+292,820
New +$11M
BAX icon
72
Baxter International
BAX
$12.8B
$11.3M 0.24%
+299,715
New +$11.5M
ALBO
73
DELISTED
Albireo Pharma Inc
ALBO
$11.2M 0.24%
+89,678
New +$9.33M
AMBI
74
DELISTED
Ambit Biosciences Corp
AMBI
$10.4M 0.22%
+1,490,769
New +$10.7M
NBIX icon
75
Neurocrine Biosciences
NBIX
$18.2B
$10.3M 0.22%
+768,000
New +$9.43M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for OrbiMed, which disclosed 127 positions worth $4.72B. Its ten largest holdings account for 38% of the portfolio.

Its largest position is Amgen: 2,619,400 shares worth $258M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, followed by Financials and Technology.

  • OrbiMed's largest Q2 2013 buy was Amgen: 2,619,400 shares worth $258M.
  • OrbiMed's ten largest holdings make up 38% of its $4.72B portfolio in Q2 2013.
  • OrbiMed disclosed 127 positions in Q2 2013, its first 13F filing on record.

Based on OrbiMed's 13F filing for Q2 2013, filed 14 Aug 2013.